Rankings
▼
Calendar
IOVA
Iovance Biotherapeutics, Inc.
$2B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$31M
+12969.7% YoY
Gross Profit
-$262,000
-0.8% margin
Operating Income
-$102M
-327.6% margin
Net Income
-$97M
-312.2% margin
EPS (Diluted)
$-0.34
QoQ Revenue Growth
+4250.5%
Cash Flow
Operating Cash Flow
-$98M
Free Cash Flow
-$99M
Stock-Based Comp.
$30M
Balance Sheet
Total Assets
$964M
Total Liabilities
$196M
Stockholders' Equity
$769M
Cash & Equivalents
$229M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$31M
$238,000
+12969.7%
Gross Profit
-$262,000
-$2M
+85.5%
Operating Income
-$102M
-$110M
+7.4%
Net Income
-$97M
-$107M
+8.8%
Geographic Segments
UNITED STATES
$30M
97%
Non-US
$1M
3%
← FY 2024
All Quarters
Q3 2024 →
IOVA Q2 2024 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena